Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) EPS (Weighted Average and Diluted) (2023 - 2025)

Mereo BioPharma (MREO) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.01 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 50.0% to -$0.01 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.05, a 16.67% increase, with the full-year FY2024 number at -$0.06, down 50.0% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.01 for Q3 2025 at Mereo BioPharma, roughly flat from -$0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.0 in Q2 2023 to a low of -$0.02 in Q1 2023.
  • A 3-year average of -$0.01 and a median of -$0.01 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 617.79% in 2024, then surged 50.0% in 2025.
  • Mereo BioPharma's EPS (Weighted Average and Diluted) stood at -$0.01 in 2023, then rose by 0.0% to -$0.01 in 2024, then decreased by 0.0% to -$0.01 in 2025.
  • Per Business Quant, the three most recent readings for MREO's EPS (Weighted Average and Diluted) are -$0.01 (Q3 2025), -$0.01 (Q2 2025), and -$0.02 (Q1 2025).